Fragment-based screening identifies novel targets for inhibitors of conjugative transfer of antimicrobial resistance by plasmid pKM101

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Casu, Bastien ^a   Arya, Tarun ^a   Bessette, Benoit ^a   Baron, Christian ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; BACTERIUM CONJUGATION; BINDING AFFINITY; BINDING SITE; CRYSTALLIZATION; DIMERIZATION; FLUOROMETRY; GENE TRANSFER; MACHINE; PLASMID; TYPE IV SECRETION SYSTEM; ANTAGONISTS AND INHIBITORS; BACTERIAL INFECTION; BACTERIUM; CHEMISTRY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MICROBIOLOGY; MOLECULAR DOCKING; MOLECULAR LIBRARY; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; PHARMACOLOGY; PROCEDURES; PROTEIN MULTIMERIZATION;

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; CONJUGATION, GENETIC; DRUG DESIGN; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; HUMANS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR TARGETED THERAPY; PLASMIDS; PROTEIN MULTIMERIZATION; SMALL MOLECULE LIBRARIES; TYPE IV SECRETION SYSTEMS;

EID: 85032823798     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-14953-1     Document Type: Article

References (23)

1. Chandran Darbari, V. & Waksman, G. Structural Biology of Bacterial Type IV Secretion Systems. Annu Rev Biochem 84, 603-629, https://doi.org/10.1146/annurev-biochem-062911-102821 (2015).
2. Trokter, M., Felisberto-Rodrigues, C., Christie, P. J. & Waksman, G. Recent advances in the structural and molecular biology of type IV secretion systems. Current opinion in structural biology 27C, 16-23, https://doi.org/10.1016/j.sbi.2014.02.006 (2014).
3. Low, H. H. et al. Structure of a type IV secretion system. Nature 508, 550-553, https://doi.org/10.1038/nature13081 (2014).
4. Fronzes, R. et al. Structure of a type IV secretion system core complex. Science 323, 266-268, https://doi.org/10.1126/ science.1166101 (2009).
5. Chandran, V. et al. Structure of the outer membrane complex of a type IV secretion system. Nature 462, 1011-1015, https://doi. org/10.1038/nature08588 (2009).
6. Brown, E. D. & Wright, G. D. Antibacterial drug discovery in the resistance era. Nature 529, 336-343, https://doi.org/10.1038/ nature17042 (2016).
7. Ruer, S., Pinotsis, N., Steadman, D., Waksman, G. & Remaut, H. Virulence-targeted Antibacterials: Concept, Promise, and Susceptibility to Resistance Mechanisms. Chem Biol Drug Des 86, 379-399, https://doi.org/10.1111/cbdd.12517 (2015).
8. Baron, C. Antivirulence drugs to target bacterial secretion systems. Curr Opin Microbiol 13, 100-105, https://doi.org/10.1016/j. mib.2009.12.003 (2010).
9. Zambelloni, R., Marquez, R. & Roe, A. J. Development of antivirulence compounds: a biochemical review. Chem Biol Drug Des 85, 43-55, https://doi.org/10.1111/cbdd.12430 (2015).
10. Hi lleringmann, M. et al. Inhibitors of Helicobacter py lori ATPase C agalpha blo ck CagA t ransp ort and c ag vir ulence. Microbiolog y 152, 2919-2930 (2006).
11. Paschos, A. et al. An In Vi v o High-Troughput Screening Approach Targeting the Type IV Secretion System Component VirB8 Identifed Inhibitors of Brucella abortus 2308 Proliferation. Infect Immun 79, 1033-1043, https://doi.org/10.1128/IAI.00993-10 (2011).
12. Smith, M. A. et al. Identification of the Binding Site of Brucella VirB8 Interaction Inhibitors. Chem Biol 19, 1041-1048, https://doi. org/10.1016/j.chembiol.2012.07.007 (2012).
13. Casu, B. et al. Str uctural analysis and inhibition of TraE f rom the pKM101 type IV secretion system. J Biol. Chem. 291, 23817-23829 (2016).
14. Sharifahmadian, M. et al. Monomer-to-dimer transition of Brucella suis type IV secretion system component VirB8 induces conformational changes. The FEBS journal 284, 1218-1232, https://doi.org/10.1111/febs.14049 (2017).
15. Silvestre, H. L., Blundell, T. L., Abell, C. & Ciulli, A. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Proceedings of the National Academy of Sciences of the United States of America 110, 12984-12989, https://doi.org/10.1073/pnas.1304045110 (2013).
16. Mashalidis, E. H., Sledz, P., Lang, S. & Abell, C. A three-stage biophysical screening cascade for fragment-based drug discovery. Nature protocols 8, 2309-2324, https://doi.org/10.1038/nprot.2013.130 (2013).
17. Gillespie, J. J. et al. Structural Insight into How Bacteria Prevent Interference between Multiple Divergent Type IV Secretion Systems. MBio 6, https://doi.org/10.1128/mBio.01867-15 (2015).
18. Bailey, S., Ward, D., Middleton, R., Grossmann, J. G. & Zambryski, P. Agrobacterium tumefaciens VirB8 structure reveals potential protein-protein interactions sites. Proc. Natl. Acad. Sci. USA 103, 2582-2587 (2006).
19. Goessweiner-Mohr, N. et al. The 2.5 A structure of the enterococcus conjugation protein TraM resembles VirB8 type IV secretion proteins. The Journal of biological chemistry 288, 2018-2028, https://doi.org/10.1074/jbc.M112.428847 (2013).
20. Terradot, L. et al. Crystal Structures of the periplasmic domains of two core subunits of the bacterial type IV secretion system, VirB8 from Brucella suis and ComB10 from Helicobacter pylori. Proc. Natl. Acad. Sci. USA 102, 4596-4601 (2005).
21. Wang, D. et al. Ident ification of bac teri al target proteins for the s a lic ylidene ac ylhydrazide class of virulence-block ing comp ounds. The Journal of biological chemistr y 286, 29922-29931, https://doi.org/10.1074/jbc.M111.233858 (2011).
22. Adams, P. D. et al. PHENIX: building new sofware for automated crystallographic structure determination. Acta crystallographica. Section D, Biological crystallography 58, 1948-1954, doi:S0907444902016657 [pii] (2002).
23. Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efcient optimization, and multithreading. J. Comput. Chem. 31, 455-461 (2010).